Elexacaftor (VX-445)

製品コードS8851 バッチS885101

印刷

化学情報

 Chemical Structure Synonyms N/A Storage
(From the date of receipt)
3 years -20°C powder
化学式

C26H34F3N7O4S

分子量 597.65 CAS No. 2216712-66-0
Solubility (25°C)* 体外 DMSO 100 mg/mL (167.32 mM)
Water Insoluble
Ethanol Insoluble
体内 (毎回新しく調製した物を用意してください)
Homogeneous suspension
CMC-NA
≥5mg/ml Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution
5%DMSO 40%PEG300 5%Tween80 50%ddH2O

この製剤はselleckのラボで検証済みです。上記の溶解方法がご要望を満たさない場合、selleckの営業担当までお問い合わせ頂ければ、個別の試験を行います。

2.500mg/ml (4.18mM) Taking the 1 mL working solution as an example, add 50 μL of 50 mg/ml clarified DMSO stock solution to 400 μL PEG300, mix evenly to clarify it; add 50 μL Tween-80 to the above system, mix evenly to clarify it; then continue to add 500 μL ddH2O Dilute to 1 mL. The mixed solution should be used immediately for optimal results. 
Clear solution
5%DMSO 95% Corn oil

この製剤はselleckのラボで検証済みです。上記の溶解方法がご要望を満たさない場合、selleckの営業担当までお問い合わせ頂ければ、個別の試験を行います。

5.000mg/ml (8.37mM) Taking the 1 mL working solution as an example, add 50 μL of 100 mg/mL clarified DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results. 
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

溶剤液(一定の濃度)を調合する

生物活性

製品説明 Elexacaftor (VX-445) is a next-generation cystic fibrosis transmembrane conductance regulator (CFTR) corrector.This is a compound which is not chiral purity.
in vitro

The pendrin-dependent increase in cystic fibrosis transmembrane conductance regulator (CFTR) current is additive with the CFTR modulator elexacaftor.[2]

プロトコル(参考用のみ)

細胞アッセイ 細胞株 Human bronchial epithelial cells from DeltaF508/DeltaF508 Cystic Fibrosis patients (CF HBECs)
濃度 3 µM
反応時間 48 h
実験の流れ

Using Chamber recordings from DeltaF508/DeltaF508 CF HBEC epithelia were treated with the LIE triple combination for 48 h plus and minus 10 ng/mL IL-13 and/or 10 micromol/L niflumic acid (for 30 minutes) again. Transepithelial current (Isc) and conductance (Gt) were measured.

(Data sourced from selleck products)

参考

  • https://pubmed.ncbi.nlm.nih.gov/30334692/
  • https://pubmed.ncbi.nlm.nih.gov/32923987/

Selleckの高級品が、幾つかの出版された研究調査結果(以下を含む)で使われた:

ACE-tRNAs are a platform technology for suppressing nonsense mutations that cause cystic fibrosis [ Nucleic Acids Res, 2025, 53(13)gkaf675] PubMed: 40650978
Endometrium-derived organoids from cystic fibrosis patients and mice as new models to study disease-associated endometrial pathobiology [ Cell Mol Life Sci, 2025, 82(1):109] PubMed: 40074868
CFTR negatively reprograms Th2 cell responses, and CFTR potentiation restrains allergic airway inflammation [ JCI Insight, 2025, 10(9)e191098] PubMed: 40131363
Human induced pluripotent stem cells for in vitro modeling of impaired mucociliary clearance in cystic fibrosis lung disease [ Stem Cell Res Ther, 2025, 16(1):573] PubMed: 41116195
In silico, in vitro and ex vivo characterization of cystic fibrosis transmembrane conductance regulator pathogenic variants localized in the fourth intracellular loop and their rescue by modulators [ Br J Pharmacol, 2025, 10.1111/bph.70176] PubMed: 40831301
Inflammation-induced loss of CFTR-expressing airway ionocytes in non-eosinophilic asthma [ Respirology, 2025, 30(1):25-40] PubMed: 39358991
Global functional genomics reveals GRK5 as a cystic fibrosis therapeutic target synergistic with current modulators [ iScience, 2025, 28(3):111942] PubMed: 40040803
Human Induced Lung Organoids: A Promising Tool for Cystic Fibrosis Drug Screening [ Int J Mol Sci, 2025, 26(2)437] PubMed: 39859153
Molecular and pharmacological evaluation of rare, cystic fibrosis-causing missense mutations of the CFTR channel [ J Physiol, 2025, 603(19):5437-5453] PubMed: 40785054
Inhibitors of the ubiquitin‑proteasome system rescue cellular levels and ion transport function of pathogenic pendrin (SLC26A4) protein variants [ Int J Mol Med, 2025, 55(5)69] PubMed: 40052591

長期の保管のために-20°Cの下で製品を保ってください。

人間や獣医の診断であるか治療的な使用のためにでない。

各々の製品のための特定の保管と取扱い情報は、製品データシートの上で示されます。大部分のSelleck製品は、推薦された状況の下で安定です。製品は、推薦された保管温度と異なる温度で、時々出荷されます。長期の保管のために必要とされてそれと異なる温度で、多くの製品は、短期もので安定です。品質を維持するが、夜通しの積荷のために最も経済的な貯蔵状況を用いてあなたの送料を保存する状況の下に、製品が出荷されることを、我々は確実とします。製品の受領と同時に、製品データシートの上で貯蔵推薦に従ってください。